Founded in 2023, Paris-based Spore Biotechnologies (branded Spore.Bio) builds full-stack platforms that combine proprietary biophotonics hardware with machine-learning models to identify microbes at the single-cell level in real time. Traditional microbiological assays take five to twenty days and require off-site labs; Spore’s solution offers immediate, on-site diagnostics by capturing visible, UV, and near-infrared spectral fingerprints from samples and analyzing them with a foundational model trained on millions of images. The technology integrates with an in-house dashboard that gives manufacturers continuous, traceable insight into microbial activity. To accelerate scientific discovery, the company has created Spore.Labs, an AI-native research arm that will publish open datasets and collaborate with academic and clinical partners. Spore.Bio has raised €29.9 million ($35 million) in equity financing to date, including a €22 million Series A led by Singular in February 2023. The company has begun hiring aggressively, expecting to add 30 scientists by 2026. Its new funding and access to Google Cloud resources further strengthen its R&D and commercialization roadmap.

Total raised

$32M

Funding rounds

3

Latest round

Series A

Latest activity

Feb 2025